Key result
CVD prevention yields ~\$6,000 per QALY more favorable cost-effectiveness than treatment interventions.
Why the study?
Are cardiovascular disease preventive measures more cost-effective than treatment interventions relative to U.S. national spending?
Are cardiovascular disease preventive measures more cost-effective than treatment interventions relative to U.S. national spending?
Linking national cardiovascular expenditure data with cost-effectiveness analyses demonstrates that while median cost per QALY across CVD spending categories falls below the $50,000 threshold, preventive measures—especially for hypertension—generally offer more favorable value than treatments.
Answers are grounded in this paper and cite their sources.
Supports prioritizing prevention in CVD resource allocation; extends cost-effectiveness analyses by integrating national spending data.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Miller et al. (2012) studied Cardiovascular disease. Cardiovascular disease preventive interventions vs. Cardiovascular disease treatment interventions was evaluated on Incremental cost-effectiveness ratio (2010 U.S. dollars per quality-adjusted life-year [QALY]). Cardiovascular disease preventive measures had a median cost-effectiveness ratio nearly $6,000 per QALY more favorable than treatment interventions, with hypertension prevention at $5,754 per QALY.
Synapse has enriched 10 related papers. Consider them for comparative context: